Table 1.
Characteristics of 1,011 stage III colon cancer patients by post-diagnostic intake of marine ω-3 PUFAs
| Characteristic, median [interquartile range] or N (%) | Quartile of marine ω-3 PUFA intake | P-value | |||
|---|---|---|---|---|---|
|
| |||||
| 1 | 2 | 3 | 4 | ||
| N | 252 | 253 | 253 | 253 | |
| Median marine ω-3 PUFA intake, g/d | 0.09 [0.07, 0.11] | 0.15 [0.14, 0.17] | 0.23 [0.21, 0.25] | 0.40 [0.33, 0.57] | |
| Male | 156 (62) | 137 (54) | 144 (57) | 132 (52) | 0.14 |
| Age, y | 60 [50, 69] | 60 [51, 68] | 61 [53, 70] | 60 [52, 69] | 0.21 |
| Race | 0.007 | ||||
| White | 235 (93) | 229 (91) | 224 (89) | 211 (83) | |
| Black | 8 (3) | 16 (6) | 20 (8) | 21 (8) | |
| Other | 9 (4) | 8 (3) | 9 (4) | 21 (8) | |
| Baseline performance status | 0.25 | ||||
| Fully active | 184 (73) | 193 (76) | 188 (74) | 177 (70) | |
| Ambulatory but restricted in strenuous activity | 65 (26) | 57 (23) | 60 (24) | 66 (26) | |
| Unknown | 3 (1) | 3 (1) | 5 (2) | 10 (4) | |
| Invasion through bowel wall | 0.44 | ||||
| T1–T2 | 33 (13) | 31 (12) | 30 (12) | 42 (17) | |
| T3–T4 | 202 (80) | 210 (83) | 204 (81) | 191 (75) | |
| Unknown | 17 (7) | 12 (5) | 19 (8) | 20 (8) | |
| Positive lymph nodes | 0.53 | ||||
| 1–3 (N1) | 154 (61) | 161 (64) | 154 (61) | 166 (66) | |
| ≥4 (N2) | 94 (37) | 89 (35) | 94 (37) | 79 (31) | |
| Unknown | 4 (2) | 3 (1) | 5 (2) | 8 (3) | |
| Clinical bowel abnormality | |||||
| Perforation | 10 (4) | 13 (5) | 13 (5) | 7 (3) | 0.70 |
| Obstruction | 52 (21) | 64 (25) | 50 (20) | 56 (22) | 0.37 |
| Grade of differentiation | 0.39 | ||||
| Well | 11 (4) | 18 (7) | 10 (4) | 18 (7) | |
| Moderate | 177 (70) | 171 (68) | 176 (70) | 177 (70) | |
| Poor | 61 (24) | 61 (24) | 60 (24) | 50 (20) | |
| Unknown | 3 (1) | 3 (1) | 7 (3) | 8 (3) | |
| Treatment arm | 0.97 | ||||
| Fluorouracil + leucovorin | 129 (51) | 125 (49) | 129 (51) | 130 (51) | |
| Irinotecan, fluorouracil, leucovorin | 123 (49) | 128 (51) | 124 (49) | 123 (49) | |
| Smoking status | <0.001 | ||||
| Current | 32 (13) | 32 (13) | 17 (7) | 22 (9) | |
| Past | 109 (43) | 113 (45) | 98 (39) | 126 (50) | |
| Never | 111 (44) | 100 (40) | 136 (54) | 104 (41) | |
| Unknown | 0 (0) | 8 (3) | 2 (1) | 1 (0) | |
| Aspirin user | 22 (9) | 21 (8) | 17 (7) | 21 (8) | 0.52 |
| Fish oil supplement user | 0 (0) | 0 (0) | 0 (0) | 24 (9) | <0.001 |
| Energy intake, kcal/d | 1854 [1454, 2334] | 1860 [1521, 2294] | 2001 [1542, 2460] | 1850 [1505, 2240] | 0.05 |
| BMI, kg/m2 | 27.9 [24.5, 31.9] | 27.9 [24.0, 32.4] | 27.6 [24.4, 31.4] | 27.4 [24.5, 31.5] | 0.80 |
| Physical activity, MET h/wk | 5.3 [1.5, 16.9] | 6.1 [2.0, 17.3] | 7.7 [2.6, 17.0] | 9.0 [3.5, 22.0] | 0.004 |